Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aileron Therapeutics Inc (ALRN)

Aileron Therapeutics Inc (ALRN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 38,394
  • Shares Outstanding, K 29,086
  • Annual Sales, $ 0 K
  • Annual Income, $ -29,370 K
  • 60-Month Beta 2.89
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.81

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.18
  • Number of Estimates 2
  • High Estimate -0.17
  • Low Estimate -0.18
  • Prior Year -0.26
  • Growth Rate Est. (year over year) +30.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4600 +252.17%
on 05/04/20
1.6300 -0.61%
on 05/29/20
+1.0665 (+192.68%)
since 04/29/20
3-Month
0.2500 +548.00%
on 03/12/20
1.6300 -0.61%
on 05/29/20
+1.0353 (+177.07%)
since 02/28/20
52-Week
0.2500 +548.00%
on 03/12/20
1.6300 -0.61%
on 05/29/20
+0.6200 (+62.00%)
since 05/29/19

Most Recent Stories

More News
Thinking about buying stock in PhaseBio Pharmaceuticals, Aileron Therapeutics, JetBlue Airways, Aurora Cannabis, or Remark Holdings?

ALRN : 1.6200 (+22.73%)
ACB : 14.08 (-8.21%)
Aileron Therapeutics Announces Initiation of Expansion Cohort and First Patient Enrolled into Expansion Cohort of Phase 1b/2 Study of ALRN-6924 as a Chemoprotection Agent

Aileron Therapeutics (NASDAQ:ALRN) announced today the expansion of one of the dose levels in the dose optimization part of its Phase 1b/2 clinical trial evaluating ALRN-6924 as an agent to protect patients...

ALRN : 1.6200 (+22.73%)
Aileron Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

Enrollment completed in the dose optimization part of the ongoing Phase 1b/2 clinical trial of ALRN-6924 as a chemoprotection agent in cancer patients

ALRN : 1.6200 (+22.73%)
Aileron Therapeutics Announces Plans to Release Interim Results from its Phase 1b/2 Myelopreservation Study in Mid-2020

Presentation of interim results from the dose-optimization part of the Phase 1b myelopreservation study

ALRN : 1.6200 (+22.73%)
Aileron Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

Phase 1b/2 clinical trial of ALRN-6924 as a myelopreservation agent for the protection against chemotherapy-induced toxicity in small cell lung cancer started dosing patients September 2019; interim data...

ALRN : 1.6200 (+22.73%)
Aileron Therapeutics Announces the Promotion of Richard J. Wanstall to Chief Financial Officer and Treasurer

Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, announced today the promotion of Richard J. Wanstall to Chief Financial Officer and...

ALRN : 1.6200 (+22.73%)
Aileron Therapeutics Reports Third Quarter 2019 Results

Announced positive interim results from its ongoing Phase 2a clinical trial evaluating the combination of ALRN-6924 and Pfizer's IBRANCE(R) (palbociclib) for the treatment of patients with tumors harboring...

ALRN : 1.6200 (+22.73%)
Aileron Therapeutics to Report Third Quarter 2019 Financial Results on November 7th

Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, today announced that the Company will host a conference call and webcast at 8:30 a.m....

ALRN : 1.6200 (+22.73%)
Aileron Therapeutics Announces Positive Nonclinical Myelopreservation Results for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference

Nonclinical research results show that ALRN-6924 prevented the toxic side effects of chemotherapy in normal cells and enhanced the anti-cancer activity of chemotherapy

ALRN : 1.6200 (+22.73%)
Aileron to Present Nonclinical Myelopreservation Data for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference on October 29th

Nonclinical research showed that ALRN-6924 prevented the toxic side effects of chemotherapy in normal cells without inhibiting the anti-cancer activity of chemotherapy.

ALRN : 1.6200 (+22.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade ALRN with:

Business Summary

Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in developing and commercializing a novel class of therapeutics primarily in the United States. The companys lead product includes ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers...

See More

Key Turning Points

2nd Resistance Point 1.7667
1st Resistance Point 1.6933
Last Price 1.6200
1st Support Level 1.4833
2nd Support Level 1.3467

See More

52-Week High 1.6300
Last Price 1.6200
Fibonacci 61.8% 1.1028
Fibonacci 50% 0.9400
Fibonacci 38.2% 0.7772
52-Week Low 0.2500

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar